Amazing

Cheng Han Ng JAMA Network Open We also found the same in our multi-centre UK study!! Aetiology clearly plays an important role. More research needed 🔍 pubmed.ncbi.nlm.nih.gov/40337094/

In this consortium study of academic centres in Singapore, Japan, Korea, and Australia JAMA Network Open by Yong Loo Lin School of Medicine student Ryan Lim, HCC surveillance was a/w ⬆️survival, but the benefit appeared less consistent in MASLD/ALD. Cheng Han Ng Karn Wijarnpreecha Anand V Kulkarni

🌍 Our first online meeting for CORE (Cirrhosis Outcomes & Research Endeavors)! Founded by Myself, Mark Muthiah and Hirokazu Takahashi, CORE united 11 sites (🇸🇬🇺🇸🇮🇳🇨🇳🇭🇰🇹🇭🇯🇵🇺🇸🇸🇬🇹🇭🇮🇳) to study compensated cirrhosis with 3500+ patients, with more joining soon from 🇺🇸🇰🇷🇦🇺🇬🇧 🇯🇵🇯🇵.

#ICOMES2025 was fabulous. Thankful to my friend, Dr Moon for inviting me to the faculty dinner with K-pop appearance! Legendary conference ❤️ Korea’s great food is contradictory to the conference topic though!

#LiverTwitter Read our new meta-analysis in CGH: Patients with MASLD + advanced fibrosis face a real risk of HCC, even without cirrhosis. 📈 Incidence climbs from ~0.8% at 1 yr → ~9% at 10 yrs. 🔗 cghjournal.org/article/S1542-…

#LiverTwitter Excited to share our new study in Scientific Reports! 🎉 We developed a simple formula using age, trunk fat & muscle mass (via BIA) to estimate liver steatosis in MASLD. 📈 eCAP performed well (AUROC ~0.80). 🔗 nature.com/articles/s4159…

#LiverTwitter Grateful to be listed (again) in Stanford’s Top 2% Scientists this year 🧑‍🔬📊& 2nd year in a row 🙏 Big thanks to mentors, collaborators & colleagues who make the journey possible. Excited to keep learning & building 🚀✨

#LiverTwitter Our new study published in APT! where "Less than 10% of patients received the recommended biannual ultrasound scans for surveillance."😱 onlinelibrary.wiley.com/doi/10.1111/ap… Karn Wijarnpreecha asako Daniel Huang Mark Muthiah Pojsakorn Dan Danpanichkul, MD

#LiverTwitter Excited to share our latest study in CGH Using >44,000 SRTR waitlist registrants, we found that while MELD 3.0 reclassifies many MASH patients, it doesn’t translate into better transplant access despite higher predicted mortality risk. cghjournal.org/article/S1542-…

#LiverTwitter While I was unable to attend #TLM2025 , very happy to see my CORE (cirrhosis outcomes and research endeavour) continues its growth to 20 sites in 1 year! 😍 We have completed and submitted 3 manuscripts, collected over 4000 patients and working on another 5 papers!